0001599901-24-000044.txt : 20240315 0001599901-24-000044.hdr.sgml : 20240315 20240315161224 ACCESSION NUMBER: 0001599901-24-000044 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240313 FILED AS OF DATE: 20240315 DATE AS OF CHANGE: 20240315 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MacLean Michael F CENTRAL INDEX KEY: 0001383731 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39321 FILM NUMBER: 24754876 MAIL ADDRESS: STREET 1: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avidity Biosciences, Inc. CENTRAL INDEX KEY: 0001599901 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461336960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE STREET 2: SUITE 125 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-401-7900 MAIL ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE STREET 2: SUITE 125 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Avidity Biosciences LLC DATE OF NAME CHANGE: 20161227 FORMER COMPANY: FORMER CONFORMED NAME: Avidity NanoMedicines LLC DATE OF NAME CHANGE: 20140211 4 1 wk-form4_1710533514.xml FORM 4 X0508 4 2024-03-13 0 0001599901 Avidity Biosciences, Inc. RNA 0001383731 MacLean Michael F C/O AVIDITY BIOSCIENCES, INC. 10578 SCIENCE CENTER DRIVE, SUITE 125 SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer 1 Common Stock 2024-03-13 4 M 0 40000 8.82 A 84093 D Common Stock 2024-03-13 4 S 0 40000 24.519 D 44093 D Stock Option (Right to Buy) 8.82 2024-03-13 4 M 0 40000 0 D 2030-05-14 Common Stock 40000 244427 D Includes the following securities previously acquired by the Reporting Person: (i) 39,384 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.44 to $24.67. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the shares subject to the option vested on May 15, 2021, and 1/48th of the original number of shares subject to the option will vest monthly thereafter. /s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact 2024-01-23